Heron Therapeutics (HRTX) Tops Q3 EPS by 12c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.17), $0.12 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $31.43 million versus the consensus estimate of $32.75 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Worthington Industries (WOR) Misses Q4 EPS by 9c